{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:42:59Z","timestamp":1792813379333,"version":"4.5.0"},"reference-count":35,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.1620\/tjem.2025.j158","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:08:30Z","timestamp":1769638110000},"page":"23-30","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Cystatin SN Inactivates AKT Pathway to Decrease Cell Proliferation, Migration, and Invasion in Thyroid Cancer"],"prefix":"10.1620","volume":"270","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"Abrahamson, M., Alvarez-Fernandez, M. &amp; Nathanson, C.-M. (2003)  Cystatins.  <i>Biochem. Soc. Symp.<\/i>, 70, 179-199. https:\/\/doi.org\/10.1042\/bss0700179","DOI":"10.1042\/bss0700179"},{"key":"2","doi-asserted-by":"publisher","unstructured":"Boucai, L., Zafereo, M. &amp; Cabanillas, M.E. (2024)  Thyroid Cancer: A Review.  <i>JAMA<\/i>, 331, 425-435. https:\/\/doi.org\/10.1001\/jama.2023.26348","DOI":"10.1001\/jama.2023.26348"},{"key":"3","doi-asserted-by":"publisher","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I. &amp; Jemal, A. (2024)  Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  <i>CA Cancer J. Clin.<\/i>, 74, 229-263. https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"4","doi-asserted-by":"publisher","unstructured":"Breznik, B., Mitrovi\u0107, A., Lah, T.T. &amp; Kos, J. (2019)  Cystatins in cancer progression: More than just cathepsin inhibitors.  <i>Biochimie<\/i>, 166, 233-250. https:\/\/doi.org\/10.1016\/j.biochi.2019.05.002","DOI":"10.1016\/j.biochi.2019.05.002"},{"key":"5","doi-asserted-by":"publisher","unstructured":"Cui, Y., Sun, D., Song, R., Zhang, S., Liu, X., Wang, Y., Meng, F., Lan, Y., Han, J., Pan, S., Liang, S., Zhang, B., Guo, H., Liu, Y., Lu, Z., et al. (2019)  Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis.  <i>J. Cell. Physiol.<\/i>, 234, 22623-22634. https:\/\/doi.org\/10.1002\/jcp.28828","DOI":"10.1002\/jcp.28828"},{"key":"6","doi-asserted-by":"publisher","unstructured":"Huang, G., Lu, L., You, Y., Li, J. &amp; Zhang, K. (2024)  Knockdown of ENO1 promotes autophagy dependent-ferroptosis and suppresses glycolysis in breast cancer cells via the regulation of CST1.  <i>Drug Dev. Res.<\/i>, 85, e70004. https:\/\/doi.org\/10.1002\/ddr.70004","DOI":"10.1002\/ddr.70004"},{"key":"7","doi-asserted-by":"publisher","unstructured":"Jiang, J., Liu, H.L., Tao, L., Lin, X.Y., Yang, Y.D., Tan, S.W. &amp; Wu, B. (2018)  Let-7d inhibits colorectal cancer cell proliferation through the CST1\/p65 pathway.  <i>Int. J. Oncol.<\/i>, 53, 781-790. https:\/\/doi.org\/10.3892\/ijo.2018.4419","DOI":"10.3892\/ijo.2018.4419"},{"key":"8","doi-asserted-by":"publisher","unstructured":"Jin, S., Borkhuu, O., Bao, W. &amp; Yang, Y.T. (2016)  Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.  <i>J. Clin. Med. Res.<\/i>, 8, 284-296. https:\/\/doi.org\/10.14740\/jocmr2480w","DOI":"10.14740\/jocmr2480w"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Kada, F., Saji, M. &amp; Ringel, M.D. (2004)  Akt: a potential target for thyroid cancer therapy.  <i>Curr. Drug Targets Immune. Endocr. Metabol. Disord.<\/i>, 4, 181-185. https:\/\/doi.org\/10.2174\/1568008043339857","DOI":"10.2174\/1568008043339857"},{"key":"10","doi-asserted-by":"publisher","unstructured":"Lai, Y., Wang, Y., Wu, Y., Wu, M., Xing, S., Xie, Y., Chen, S., Li, X., Zhang, A., He, Y., Li, H., Dai, S., Wang, J., Lin, S., Bai, Y., et al. (2022)  Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.  <i>Cancer Control<\/i>, 29, 10732748221104661. https:\/\/doi.org\/10.1177\/10732748221104661","DOI":"10.1177\/10732748221104661"},{"key":"11","doi-asserted-by":"publisher","unstructured":"Landa, I. &amp; Cabanillas, M.E. (2024)  Genomic alterations in thyroid cancer: biological and clinical insights.  <i>Nat. Rev. Endocrinol.<\/i>, 20, 93-110. https:\/\/doi.org\/10.1038\/s41574-023-00920-6","DOI":"10.1038\/s41574-023-00920-6"},{"key":"12","doi-asserted-by":"publisher","unstructured":"Lee, C., Bongcam-Rudloff, E., Sollner, C., Jahnen-Dechent, W. &amp; Claesson-Welsh, L. (2009)  Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein.  <i>Front. Biosci.<\/i> (<i>Landmark Ed.<\/i>), 14, 2911-2922. https:\/\/doi.org\/10.2741\/3422","DOI":"10.2741\/3422"},{"key":"13","doi-asserted-by":"publisher","unstructured":"Li, D., Wang, Y., Dong, C., Chen, T., Dong, A., Ren, J., Li, W., Shu, G., Yang, J., Shen, W., Qin, L., Hu, L. &amp; Zhou, J. (2023)  CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1.  <i>Oncogene<\/i>, 42, 83-98. https:\/\/doi.org\/10.1038\/s41388-022-02537-x","DOI":"10.1038\/s41388-022-02537-x"},{"key":"14","doi-asserted-by":"publisher","unstructured":"Liu, Y., Ma, H., Wang, Y., Du, X. &amp; Yao, J. (2019)  Cystatin SN Affects Cell Proliferation by Regulating the ER<i>\u03b1<\/i>\/PI3K\/AKT\/ER<i>\u03b1<\/i> Loopback Pathway in Breast Cancer.  <i>Onco Targets Ther.<\/i>, 12, 11359-11369. https:\/\/doi.org\/10.2147\/ott.S234328","DOI":"10.2147\/OTT.S234328"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Liu, Y. &amp; Yao, J. (2019)  Research progress of cystatin SN in cancer.  <i>Onco Targets Ther.<\/i>, 12, 3411-3419. https:\/\/doi.org\/10.2147\/ott.S194332","DOI":"10.2147\/OTT.S194332"},{"key":"16","doi-asserted-by":"publisher","unstructured":"Luan, X., Peng, X., Hui, G. &amp; Wei, Z. (2025)  TFAP2A Promotes Cell Progression and Suppresses Ferroptosis in Lung Adenocarcinoma via Activating Transcription of CST1.  <i>J. Biochem. Mol. Toxicol.<\/i>, 39, e70087. https:\/\/doi.org\/10.1002\/jbt.70087","DOI":"10.1002\/jbt.70087"},{"key":"17","doi-asserted-by":"publisher","unstructured":"Luo, F.F., Wang, J., Zhang, Z.F., Lin, S.T., Huang, T.J., Liu, B.Q., Fan, M.L., Peng, L.X., Zheng, S.T., Yang, C.F. &amp; Huang, B.J. (2023)  SPI1-Mediated Upregulation of the CST1 Gene as an Independent Poor Prognostic Factor Accelerates Metastasis in Esophageal Squamous Cell Carcinoma (ESCC) by Interacting with MMP2.  <i>Front. Biosci. <\/i>(<i>Landmark Ed.<\/i>), 28, 212. https:\/\/doi.org\/10.31083\/j.fbl2809212","DOI":"10.31083\/j.fbl2809212"},{"key":"18","doi-asserted-by":"publisher","unstructured":"Neumar, R.W., Xu, Y.A., Gada, H., Guttmann, R.P. &amp; Siman, R. (2003)  Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis.  <i>J. Biol. Chem.<\/i>, 278, 14162-14167. https:\/\/doi.org\/10.1074\/jbc.M212255200","DOI":"10.1074\/jbc.M212255200"},{"key":"19","doi-asserted-by":"publisher","unstructured":"Ochieng, J. &amp; Chaudhuri, G. (2010)  Cystatin superfamily.  <i>J. Health Care Poor Underserved<\/i>, 21, 51-70. https:\/\/doi.org\/10.1353\/hpu.0.0257","DOI":"10.1353\/hpu.0.0257"},{"key":"20","doi-asserted-by":"publisher","unstructured":"Oh, B.M., Lee, S.J., Cho, H.J., Park, Y.S., Kim, J.T., Yoon, S.R., Lee, S.C., Lim, J.S., Kim, B.Y., Choe, Y.K. &amp; Lee, H.G. (2017)  Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer.  <i>Cell Death Dis.<\/i>, 8, e2682. https:\/\/doi.org\/10.1038\/cddis.2017.100","DOI":"10.1038\/cddis.2017.100"},{"key":"21","doi-asserted-by":"publisher","unstructured":"Petrulea, M.S., Plantinga, T.S., Smit, J.W., Georgescu, C.E. &amp; Netea-Maier, R.T. (2015)  PI3K\/Akt\/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.  <i>Cancer Treat. Rev.<\/i>, 41, 707-713. https:\/\/doi.org\/10.1016\/j.ctrv.2015.06.005","DOI":"10.1016\/j.ctrv.2015.06.005"},{"key":"22","doi-asserted-by":"publisher","unstructured":"Qiang, J., Zhao, C., Shi, L.Q., Sun, S.R., Wang, H.K., Liu, S.L., Yang, Z.Y., Dong, P., Xiang, S.S., Wang, J.D. &amp; Shu, Y.J. (2024)  BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K\/AKT pathway and represents a therapeutic target.  <i>Gene Ther.<\/i>, 31, 594-606. https:\/\/doi.org\/10.1038\/s41434-024-00488-4","DOI":"10.1038\/s41434-024-00488-4"},{"key":"23","doi-asserted-by":"publisher","unstructured":"Shen, B., Ding, H., Ye, Y. &amp; Luo, B. (2022)  Role of the Long Intergenic Non-Protein-Coding RNA 1278\/miR-185-5p\/Cystatin SN Axis in Laryngeal Cancer Cells.  <i>J. Oncol.<\/i>, 2022, 6406943. https:\/\/doi.org\/10.1155\/2022\/6406943","DOI":"10.1155\/2022\/6406943"},{"key":"24","doi-asserted-by":"publisher","unstructured":"Shonka, D.C. Jr., Ho, A., Chintakuntlawar, A.V., Geiger, J.L., Park, J.C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A.H., Bible, K.C., Brose, M.S., Cabanillas, M.E., Dabekaussen, K., Davies, L., Dias-Santagata, D., Fagin, J.A., et al. (2022)  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.  <i>Head Neck<\/i>, 44, 1277-1300. https:\/\/doi.org\/10.1002\/hed.27025","DOI":"10.1002\/hed.27025"},{"key":"25","doi-asserted-by":"publisher","unstructured":"Viglietto, G., Amodio, N., Malanga, D., Scrima, M. &amp; De Marco, C. (2011)  Contribution of PKB\/AKT signaling to thyroid cancer.  <i>Front. Biosci. <\/i>(<i>Landmark Ed.<\/i>), 16, 1461-1487. https:\/\/doi.org\/10.2741\/3799","DOI":"10.2741\/3799"},{"key":"26","doi-asserted-by":"publisher","unstructured":"Yan, B., Ren, Y., Liu, C., Shu, L., Wang, C. &amp; Zhang, L. (2023)  Cystatin SN in type 2 inflammatory airway diseases.  <i>J. Allergy Clin. Immunol.<\/i>, 151, 1191-1203.e1193. https:\/\/doi.org\/10.1016\/j.jaci.2023.02.005","DOI":"10.1016\/j.jaci.2023.02.005"},{"key":"27","doi-asserted-by":"publisher","unstructured":"Yang, J., Luo, G., Li, C., Zhao, Z., Ju, S., Li, Q., Chen, Z., Ding, C., Tong, X. &amp; Zhao, J. (2022)  Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.  <i>BMC Cancer<\/i>, 22, 589. https:\/\/doi.org\/10.1186\/s12885-022-09685-z","DOI":"10.1186\/s12885-022-09685-z"},{"key":"28","doi-asserted-by":"publisher","unstructured":"Zaballos, M.A. &amp; Santisteban, P. (2017)  Key signaling pathways in thyroid cancer.  <i>J. Endocrinol.<\/i>, 235, R43-r61. https:\/\/doi.org\/10.1530\/joe-17-0266","DOI":"10.1530\/JOE-17-0266"},{"key":"29","doi-asserted-by":"publisher","unstructured":"Zafon, C., Gil, J., P\u00e9rez-Gonz\u00e1lez, B. &amp; Jord\u00e0, M. (2019)  DNA methylation in thyroid cancer.  <i>Endocr. Relat. Cancer<\/i>, 26, R415-r439. https:\/\/doi.org\/10.1530\/erc-19-0093","DOI":"10.1530\/ERC-19-0093"},{"key":"30","doi-asserted-by":"publisher","unstructured":"Zhang, H., Duan, H.L., Wang, S., Liu, Y., Ding, G.N. &amp; Lin, R.X. (2022)  Epigenetic signature associated with thyroid cancer progression and metastasis.  <i>Semin. Cancer Biol.<\/i>, 83, 261-268. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.026","DOI":"10.1016\/j.semcancer.2021.03.026"},{"key":"31","doi-asserted-by":"publisher","unstructured":"Zhang, L., Chen, X., Wang, J., Chen, M., Chen, J., Zhuang, W., Xia, Y., Huang, Z., Zheng, Y. &amp; Huang, Y. (2024)  Cysteine protease inhibitor 1 promotes metastasis by mediating an oxidative phosphorylation\/MEK\/ERK axis in esophageal squamous carcinoma cancer.  <i>Sci. Rep.<\/i>, 14, 4985. https:\/\/doi.org\/10.1038\/s41598-024-55544-1","DOI":"10.1038\/s41598-024-55544-1"},{"key":"32","doi-asserted-by":"publisher","unstructured":"Zhang, L., Feng, Q., Wang, J., Tan, Z., Li, Q. &amp; Ge, M. (2023a)  Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.  <i>Biochim. Biophys. Acta Rev. Cancer<\/i>, 1878, 188928. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188928","DOI":"10.1016\/j.bbcan.2023.188928"},{"key":"33","doi-asserted-by":"publisher","unstructured":"Zhang, L., Wang, D., Zhang, L. &amp; Zhu, L. (2025)  CST1 promoted gastric cancer development by activating the AKT pathway.  <i>Clinics <\/i>(<i>Sao Paulo<\/i>), 80, 100561. https:\/\/doi.org\/10.1016\/j.clinsp.2024.100561","DOI":"10.1016\/j.clinsp.2024.100561"},{"key":"34","doi-asserted-by":"publisher","unstructured":"Zhang, L., Yu, S., Yin, X., Tu, M., Cai, L., Zhang, Y., Yu, L., Zhang, S., Pan, X. &amp; Huang, Y. (2023b)  MiR-942-5p inhibits tumor migration and invasion through targeting CST1 in esophageal squamous cell carcinoma.  <i>PloS One<\/i>, 18, e0277006. https:\/\/doi.org\/10.1371\/journal.pone.0277006","DOI":"10.1371\/journal.pone.0277006"},{"key":"35","doi-asserted-by":"publisher","unstructured":"Zhang, Z. &amp; Zhan, F. (2023)  Type 2 Cystatins and Their Roles in the Regulation of Human Immune Response and Cancer Progression.  <i>Cancers <\/i>(<i>Basel<\/i>), 15, 5363. https:\/\/doi.org\/10.3390\/cancers15225363","DOI":"10.3390\/cancers15225363"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/270\/1\/270_2025.J158\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:26:53Z","timestamp":1792812413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/270\/1\/270_2025.J158\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2025.j158","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2025.J158"}}